Australia markets closed

Tiziana Life Sciences Ltd (0RP.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.62500.0000 (0.00%)
As of 08:02AM CET. Market open.
Full screen
Previous close0.6250
Open0.6250
Bid0.6250 x N/A
Ask0.6350 x N/A
Day's range0.6250 - 0.6250
52-week range0.5600 - 1.2800
Volume0
Avg. volume63
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects

    Third-party research conducted by leading U.S. academic institutions published in a peer reviewed journal Frontiers in Immunology shows a favorable safety profile for intranasally administered foralumab and immunological activity in humans Finding supports Tiziana’s intranasal foralumab monoclonal antibody platform as a new modality for the treatment of autoimmune and CNS diseasesTiziana’s fully human foralumab is the first anti-CD3 mAb which has not shown an anti-drug antibody (immune reaction)

  • GlobeNewswire

    Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

    -Company to host conference call via webcast at 10 am ET-NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Scle

  • GlobeNewswire

    Tiziana Life Sciences to Host Investor Call

    NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company plans to host an investor call and webcast on Thursday, November 10 2022 at 10 a.m. ET. Dial-in details and webcast information will be provided on the morning of November 10. About Tiziana Life Sciences Tiziana Life Sciences is a clinical-s